CIT Launches LeadScreen, a New Range of Services for Drug Candidate Selection
CIT announces today a new range of services to meet the growing needs of companies developing the drugs of tomorrow. The services, grouped under the name LeadScreen (TM), offer an array of tests designed to give an early evaluation of safety of drugs thought to have development potential.
Currently, around 20 per cent of candidate drugs fail during standard regulatory non-clinical studies, too often due to late identification of toxicological effects. Using CIT’s LeadScreen (TM), the early detection of potential toxicity can increase the chances of success when the candidate drug goes through the later stages of non-clinical development. LeadScreen (TM) offers the ability to reduce the financial cost and time associated with standard drug development practices.
LeadScreen offers:
- Precise selection of the future drug candidate. Using CIT’s expertise in toxicology, genomics and biomarker analysis, LeadScreen (TM) Tox offers a multi-criteria toxicology study. In a four-day predictive study, LeadScreen (TM) Tox combines the clinic (daily clinical examinations), clinical biology, histopathology, toxico-genomics, biomarker identification, in vivo micronuclei and toxico-kinetics.
- The evaluation of the genotoxicity of candidates using BlueScreen (TM) tests, mini-Ames and mini-micronucleus.
- The evaluation of pharmacological safety parameters, such as QT prolongation and other cardiovascular parameters in vivo.
- The definition of in vivo half-life and bioavailability.
- devTox (TM) and cardioTox (TM): LeadScreen (TM) also includes tests offered by CIT’s Wisconsin-based partner, Stemina Biomarker Discovery. These use metabolomics and embryonic human stem cells to identify biomarkers for developmental (devTox (TM) and cardiac toxicity (cardioTox (TM).
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
